![]() |
The new stock research experience is built to take
advantage of the latest browser technology.
RELATED RESOURCES |
The current research page will be phased out by summer.
Click Use New Research and get the same data you use today,
plus new tools and insights.
Snapshot:AKBAAKEBIA THERAPEUTICS INC0.3652
|
|
Company ProfileLog in for more informationAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy,… ![]() Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. ![]() Sector (GICS®)Health CareIndustry (GICS®)BiotechnologyEnvironmental, Social & Governance Summary (ESG)![]() ESG ratings enable you to leverage independent ESG research to evaluate how companies are managing ESG risks and addressing ESG opportunities. Learn more About Environmental, Social & Governance Summary (ESG)MSCI ESG RatingsEnvironmental, Social, and Governance (ESG) Flags: MSCI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide. These ratings provide an independent assessment of the sustainable investment value of public companies. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. Unlike traditional ESG risk models, MSCI's rating methodology is designed to identify risks most likely to affect equity valuations. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Individual company scores are then assigned as a percentile rank, ranging from 1 (worst ranked) to 100 (best) on the basis of these KeyMetrics® and then converted to the Red, Yellow or Green flag designation. Company Reports: In addition to a company's overall risk rating, ESG reports also include an industry rating based on a comparison between the company's risk levels in each ESG component area relative to its industry peers. Further, the ESG analysis serves as a summary of behavioral events that contributed to the company's overall risk level. Full Time Employees: 426
Executives
www.akebia.com
245 First Street, Suite 1400 1-617 871 2098 |
Analyst OpinionsThe Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More.... Log in to view the Equity Summary Score for AKBA
Log in
to view all Analyst Opinions for AKBA
Research Reports
Company Research Highlights® Report (PDF)
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Compustat ® Company Report
This generated report* has historical data on financials with interactive charts, technical indicators, and five-year peer comparison trend charts.
*Generated reports are built dynamically when you select them. Reports may not be available for some symbols. Select the link to check availability for this symbol.
AKBA Industry Comparison:Vs. Biotechnology |